Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11.

Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, Liao P, Zhou J, Zhang Q, Dow A, Saripalli AL, Kryczek I, Wei S, Szeliga W, Vatan L, Stone EM, Georgiou G, Cieslik M, Wahl DR, Morgan MA, Chinnaiyan AM, Lawrence TS, Zou W.

Cancer Discov. 2019 Sep 25. pii: CD-19-0338. doi: 10.1158/2159-8290.CD-19-0338. [Epub ahead of print]

PMID:
31554642
2.

CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy.

Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W.

Nature. 2019 May;569(7755):270-274. doi: 10.1038/s41586-019-1170-y. Epub 2019 May 1.

PMID:
31043744
3.

Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.

Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, Zhao L, Vatan L, Wen B, Shu P, Sun D, Kleer C, Wicha M, Sabel M, Tao K, Wang G, Zou W.

Cell Metab. 2018 Jul 3;28(1):87-103.e6. doi: 10.1016/j.cmet.2018.04.022. Epub 2018 May 24.

4.

Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis.

Crespo J, Wu K, Li W, Kryczek I, Maj T, Vatan L, Wei S, Opipari AW, Zou W.

J Immunol. 2018 Jul 15;201(2):814-820. doi: 10.4049/jimmunol.1700755. Epub 2018 May 25.

5.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Apr 2;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 2. No abstract available.

6.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. Erratum in: J Clin Invest. 2018 Apr 2;128(4):1708.

7.

Phenotype and tissue distribution of CD28H+ immune cell subsets.

Crespo J, Vatan L, Maj T, Liu R, Kryczek I, Zou W.

Oncoimmunology. 2017 Aug 16;6(12):e1362529. doi: 10.1080/2162402X.2017.1362529. eCollection 2017.

8.

Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.

Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, Zhao L, Vatan L, Shao I, Szeliga W, Lyssiotis C, Liu JR, Kryczek I, Zou W.

Nat Immunol. 2017 Dec;18(12):1332-1341. doi: 10.1038/ni.3868. Epub 2017 Oct 30.

9.

IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment.

Fang M, Li Y, Huang K, Qi S, Zhang J, Zgodzinski W, Majewski M, Wallner G, Gozdz S, Macek P, Kowalik A, Pasiarski M, Grywalska E, Vatan L, Nagarsheth N, Li W, Zhao L, Kryczek I, Wang G, Wang Z, Zou W, Wang L.

Cancer Res. 2017 May 15;77(10):2735-2745. doi: 10.1158/0008-5472.CAN-16-1602. Epub 2017 Mar 1.

10.

Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma.

Kryczek I, Wang L, Wu K, Li W, Zhao E, Cui T, Wei S, Liu Y, Wang Y, Vatan L, Szeliga W, Greenson JK, Roliński J, Zgodzinski W, Huang E, Tao K, Wang G, Zou W.

Oncoimmunology. 2016 Aug 12;5(8):e1105430. doi: 10.1080/2162402X.2015.1105430. eCollection 2016 Aug.

11.

Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling.

Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, Staroslawska E, Szubstarski F, Rolinski J, Grywalska E, Stanisławek A, Polkowski W, Kurylcio A, Kleer C, Chang AE, Wicha M, Sabel M, Zou W, Kryczek I.

Cancer Res. 2016 Jun 1;76(11):3156-65. doi: 10.1158/0008-5472.CAN-15-2528. Epub 2016 Apr 6.

12.

Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, Lu F, Wei S, Maj T, Peng D, He G, Vatan L, Szeliga W, Kuick R, Kotarski J, Tarkowski R, Dou Y, Rattan R, Munkarah A, Liu JR, Zou W.

Cell. 2016 May 19;165(5):1092-1105. doi: 10.1016/j.cell.2016.04.009. Epub 2016 Apr 28.

13.

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.

Nagarsheth N, Peng D, Kryczek I, Wu K, Li W, Zhao E, Zhao L, Wei S, Frankel T, Vatan L, Szeliga W, Dou Y, Owens S, Marquez V, Tao K, Huang E, Wang G, Zou W.

Cancer Res. 2016 Jan 15;76(2):275-82. doi: 10.1158/0008-5472.CAN-15-1938. Epub 2015 Nov 13.

14.

Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.

Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L, Wei S, Crespo J, Wan S, Vatan L, Szeliga W, Shao I, Wang Y, Liu Y, Varambally S, Chinnaiyan AM, Welling TH, Marquez V, Kotarski J, Wang H, Wang Z, Zhang Y, Liu R, Wang G, Zou W.

Nat Immunol. 2016 Jan;17(1):95-103. doi: 10.1038/ni.3313. Epub 2015 Nov 2.

15.

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.

Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, Kotarski J, Tarkowski R, Dou Y, Cho K, Hensley-Alford S, Munkarah A, Liu R, Zou W.

Nature. 2015 Nov 12;527(7577):249-53. doi: 10.1038/nature15520. Epub 2015 Oct 26.

16.

Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.

Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W, Welling TH.

Gastroenterology. 2014 Dec;147(6):1393-404. doi: 10.1053/j.gastro.2014.08.039. Epub 2014 Aug 30.

17.

IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.

Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, Zgodzinski W, Majewski M, Wallner G, Fang J, Huang E, Zou W.

Immunity. 2014 May 15;40(5):772-784. doi: 10.1016/j.immuni.2014.03.010. Epub 2014 May 8.

18.

Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.

Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, Kotarski J, Tarkowski R, Wicha M, Cho K, Giordano T, Liu R, Zou W.

Immunity. 2013 Sep 19;39(3):611-21. doi: 10.1016/j.immuni.2013.08.025. Epub 2013 Sep 5.

19.

Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer.

Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L, Altuwaijri S, Sparwasser T, Wang G, Keller ET, Zou W.

Oncoimmunology. 2012 Mar 1;1(2):152-161.

20.

Human TH17 cells are long-lived effector memory cells.

Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A, Lange A, Zou W.

Sci Transl Med. 2011 Oct 12;3(104):104ra100. doi: 10.1126/scitranslmed.3002949.

21.

Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.

Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W.

Int J Cancer. 2012 Jan 1;130(1):29-39. doi: 10.1002/ijc.25967. Epub 2011 Apr 8.

22.

IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer.

Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, Huang E, Greenson J, Chang A, Roliński J, Radwan P, Fang J, Wang G, Zou W.

J Immunol. 2011 Apr 1;186(7):4388-95. doi: 10.4049/jimmunol.1003251. Epub 2011 Feb 28.

23.

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W.

Blood. 2009 Aug 6;114(6):1141-9. doi: 10.1182/blood-2009-03-208249. Epub 2009 May 21.

24.

FOXP3 defines regulatory T cells in human tumor and autoimmune disease.

Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, Zou W.

Cancer Res. 2009 May 1;69(9):3995-4000. doi: 10.1158/0008-5472.CAN-08-3804. Epub 2009 Apr 21.

25.

Endogenous IL-17 contributes to reduced tumor growth and metastasis.

Kryczek I, Wei S, Szeliga W, Vatan L, Zou W.

Blood. 2009 Jul 9;114(2):357-9. doi: 10.1182/blood-2008-09-177360. Epub 2009 Mar 16.

26.

Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development.

Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, Chen L, Wang G, Zou W.

J Immunol. 2008 Nov 1;181(9):5842-6.

27.

Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis.

Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, Szeliga W, Wang Y, Liu Y, Welling TH, Elder JT, Zou W.

J Immunol. 2008 Oct 1;181(7):4733-41.

28.

Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression.

Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, Zou W.

J Immunol. 2007 Aug 1;179(3):1423-6.

Supplemental Content

Support Center